-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ripretinib (Ripretinib) is a tyrosine kinase switch control inhibitor that uses a unique dual mechanism of action to regulate the kinase switch and activation loop, thereby extensively inhibiting KIT and PDGFRα mutant kinases
Ripretinib is a tyrosine kinase switch control inhibitor that uses a unique dual mechanism of action to regulate the kinase switch and activation loop, thereby broadly inhibiting KIT and PDGFRα mutant kinase Ripretinib is A tyrosine kinase switch control inhibitor that uses a unique dual mechanism of action to regulate the kinase switch and activation loop, thereby broadly inhibiting KIT and PDGFRα mutant kinases.
The phase 3 INVICTUS study aims to characterize the tumor heterogeneity of patients with advanced GIST and to evaluate the effectiveness of reptinib in a subgroup of patients with KIT/PDGFRA mutations
Collect tumor tissue and biopsy samples of test patients for next-generation sequencing
In total, 129 patients were recruited and randomly divided into two groups, 85 in the reptinib group and 44 in the placebo group
In different mutation subgroups, the survival rate of patients in the two treatment groups
In different mutation subgroups, the survival rate of patients in the two treatment groupsRegardless of the mutation status, the progression-free survival (PFS) of patients treated with repatinib was better than that of the placebo group (hazard ratio [HR] 0.
Regardless of the mutation status, the progression-free survival (PFS) of patients treated with repatinib was better than that of the placebo group.
Reptinib has clinically significant therapeutic activity in advanced GIST patients with different mutation subgroups, suggesting that reptinib may provide a new treatment option for advanced GIST patients who have previously received ≥3 lines of TKI therapy! Reptinib has clinically significant therapeutic activity in advanced GIST patients with different mutation subgroups, suggesting that reptinib may provide a new treatment option for advanced GIST patients who have previously received ≥3 lines of TKI therapy!
Original source:
Original source:Bauer Sebastian,Heinrich Michael C,George Suzanne et al.
Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT / PDGFRA mutations in the phase 3 INVICTUS study
in this message
